Xiuhua Weng

15PUBLICATIONS
6CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cross-sectional analysisSocio-economic developmentObstetrics and gynaecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 04, 2026
Development and validation of a prognostic nomogram for predicting the progression risk of HCC after lenvatinib therapy.

|May 25, 2026
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.

|Apr 30, 2026
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China.

|Feb 24, 2026
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.

Shen Lin, Xiangzhen Wang, Lijing Yang

|Nov 20, 2025
Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study.

Yijun Cai, Shaohong Luo, Shen Lin

|Jul 10, 2025
Is the incidence and burden of cancer increasing among young individuals? An age-related analysis based on Global Burden of Disease Study and Surveillance, Epidemiology and End Results.

Yijun Cai, Xiaojia Huang, Dong Lin

Pageof 3

Frequent Collaborators

4 joint publications

Xiongwei Xu

1 joint publications

Qiuling Zhao

1 joint publications

Ruixiang Xie

1 joint publications

Shen Lin